Navigation Links
ProLindac in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... prolindac Showing High DACH Platinum Activity; Drug Well Tol...s in the Company's clinical development plan for prolindac , a novel DACH platinum drug that has shown t...lts from its Phase 2 monotherapy clinical study of prolindac (TM) in late-stage, heavily pretreated ovarian ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the v...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

... - prolindac Is Safe And Active in Recurrent Ovarian Cancer; Un... France where the level of anti-cancer activity of prolindac in a heavily-pretreated patient population compare...s in France, demonstrate the potential benefits of prolindac over current platinum therapies: one highlights th...
ProLindac in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... high dose groups achieved disease stabilization. prolindac was well tolerated overall. DALLAS, March 5 /...ffect of the approved DACH platinum, Eloxatin, and prolindac was well tolerated overall. The maximum tolerated dose of prolindac was established as well as the recommended dose le...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

...lop and commercialize Access' proprietary products prolindac and MuGard for the Republic of Korea. prolindac is Access' novel DACH platinum prodrug currently i...h a double digit royalty upon commercialization of prolindac and MuGard. In addition, in co-operation with Acce...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... prolindac Demonstrates Sustained and Significant Reductions ...Efficacy Results from an Ongoing Clinical Study of prolindac in Recurrent Ovarian Cancer." prolindac is Access' novel DACH platinum-polymer prodrug, wh...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...potential benefits for cancer therapy of combining prolindac with other anticancer agents. "These studies, whi...s year, provide further support to our belief that prolindac has the potential to become an important tool in t...he second poster demonstrates that combinations of prolindac with certain other anticancer compounds produces c...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...n San Francisco, CA. An update on Access' ongoing prolindac Phase 2 clinical study will be presented during Po...uesday, October 23, 2007 from 12:30 p.m. PDT. New prolindac preclinical data will appear in two posters presen...toxics, in human colon and ovarian cancer cells." prolindac is a novel DACH platinum prodrug which has been sh...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...titutes in France. "We are delighted to have two prolindac poster presentations at one of the most prestigiou...re platinum could be administered to patients with prolindac than oxaliplatin before the onset of toxicity. We are currently studying prolindac in a Phase 2 monotherapy trial, treating patients ...
ProLindac in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...nd that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue a...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... - Data demonstrates that prolindac should provide sustained tumor exposure to platinu...iopolymer" was presented on Monday, April 20. prolindac is Access' novel polymer-based DACH platinum prodr...ovides in vitro and ex-vivo data on the binding of prolindac to blood components, and suggests a mechanistic ra...

Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

...nd can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob . The replay can be obtained at the same link for 90 days. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals to Present at the Noble Financial Equity Conference

...ommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

...hese opportunities involve compounds that MacroChem believes show promising late-stage, pre-clinical and early clinical data. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...he Macau Special Administrative Region and Taiwan. prolindac is Access' novel DACH platinum prodrug currently i...r obtaining the necessary regulatory approvals for prolindac and commercializing the product in the Greater Chi...an of ASK. "We are excited about the potential for prolindac in China, and we are committed to bringing excitin...

Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

....wsw.com/webcast/rrshq13/accp.ob . The replay can be obtained at the same link for up to 90 days after the live presentation. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Announces $2.7 Million New Equity

... Stock will be amended. Closing of the transaction is subject to the fulfillment of customary and usual closing conditions. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...
Other Tags
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Daily Gossip reveals in its review a ... You program, who shows a unique formula to get inside ... method says that the program goes beyond mere attraction and ... You review indicates that the program was created by dating ... great techniques to make a man feel emotionally addicted. , ...
(Date:8/30/2014)... Daily Gossip reveals in its recently published review that ... by Sarah Summer, who can perfectly understand what suffering from ... program actually had to deal with this disorder, too. Her ... access it, in an all-natural holistic cure program. , So, ... cure for yeast infection. The author of this program suffered ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... Nutrition and Pharameuticals. Nutraceuticals is a source of ... ingredients from natural food sources. Nutraceutical ingredients have ... to the human body. Nutraceutical health products include ... fortified foods and more. Although nature is the ...
(Date:8/30/2014)... New York, NY (PRWEB) August 30, 2014 ... for authentic U.S. Open Tennis Championship tickets ... their customer appreciation promo/coupon code US-OPEN-2014 for all day ... (GA) seats and group sales for this prestigious Grand ... schedule is below: , 8/30/14 , US Open Tennis ...
Breaking Medicine News(10 mins):Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5
(Date:8/29/2014)... The rise of the Tibetan plateau -- the largest ... important for both its profound effect on climate and ... in GSA Bulletin , Katharine Huntington and colleagues ... -- using modern and fossil snail shells to investigate ... Tibet. , Views range widely on the timing ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have ... and enhance the process of re-engineering cells for biomedical ... network biology methods to aid stem cell engineering. Details ... are described in two back-to-back papers in the journal ... broad range of uses for all types of cell-based ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2
Other Contents